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Immune modulationAbstract Background: Soybean oligosaccharides (SBOSs) are potential prebiotics that may be
used to improve immune function. Here, we investigated the effects of intragastric administration
of SBOSs in mice to determine the effects on autochthonous intestinal microbial communities
and immunological parameters. Results E: After 22-day administration, 4.0 g kg body weight
(BW)1 SBOSs significantly enhanced the proliferation of bifidobacteria and lactic acid bacteria
(LAB) as compared to the control. This dose of SBOSs also significantly increased numbers of ente-
rococci and decreased numbers of Clostridium perfringens. Treatment with 4.0 g kg BW1 SBOSs
also significantly increased the percentage of T-lymphocytes and lymphocyte proliferation as com-
pared to the control, suggesting that SBOSs promoted cellular immunity in mice. Additionally,
4.0 g kg BW1 SBOSs induced significant differences in hemolysin production, natural killer
(NK) cell activity, phagocytic activity, cytokine production, and immunoglobulin levels compared
to the control. Conclusion: Our data demonstrated that intragastric administration of SBOSs at a
dose of 4.0 g kg BW1 improved the numbers of beneficial intestinal microbes and enhanced
immunological function of mice. Therefore, these data supported that SBOSs may have applica-
tions as a prebiotic to improve immune responses in humans. Further studies are warranted.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prebiotics are nondigestible food ingredients that beneficially
affect the host by selectively stimulating the growth and/or
activity of one or a limited number of bacteria in the colon,
thus improving host health (Gibson and Roberfroid, 1995).
Intake of prebiotics increases the number of specific bacteria
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the microbiota (Gibson and Roberfroid, 1995). Flickinger
and Fahey (2002) is usually short-chain oligosaccharides with
2–60 polymers and are not digested by human or animal diges-
tive enzymes of the upper gastrointestinal tract, but are instead
selectively fermented by some types of intestinal bacteria in the
large intestine (Patterson and Burkholder, 2003). Among the
bacteria present in the gastrointestinal tract, bifidobacteria
and lactobacilli are those that most often utilize prebiotic
oligosaccharides and are therefore the only microorganisms
able to beneficially affect the health of the host in this context
(Mikkelsen and Jensen, 2004; Vernazza et al., 2005).
Soybean oligosaccharides (SBOSs), which are isolated from
soybean seeds, are well-established prebiotics approved by the
United States Food and Drug Administration as a generally
recognized as safe (GRAS) ingredient (Chen et al., 2010;
Kim et al., 2003). SBOSs are a group of soluble oligosaccha-
rides found in soy or other legumes and consist primarily of
raffinose, stachyose, and sucrose, common components
formed by various linkages of mono- and oligosaccharides
(Zhou et al., 2012; Jianxian and Liping, 2003).
In the intestine, SBOSs can be fermented by certain bacte-
ria, such as lactobacilli and bifidobacteria. Dietary inclusion of
SBOSs will thus selectively support the growth and survival of
these bacteria in the gastrointestinal tract of animals. Indeed,
one study has shown that feeding of wheat bran oligosaccha-
rides and SBOSs results in significantly higher concentrations
of bifidobacteria and Clostridium perfringens relative to that
of fructooligosaccharide (FOS) feeding or the control, while
FOS had no effect compared to the control (Martin et al.,
1998). Furthermore, soybean meal oligosaccharides (SMOs)
have been reported to potentially promote competitive exclu-
sion of pathogens (Xu et al., 2009). Therefore, consumption
of these prebiotics may be useful for maintaining populations
of beneficial microbes in the gut.
In addition, SBOSs may benefit immune function by stim-
ulating the growth and metabolism of protective commensal
intestinal bacteria, part of the first line of defense in the gas-
trointestinal tract (Boehm et al., 2005). Indeed, prebiotics
can enhance nonspecific defense mechanisms and increase
resistance to infectious diseases by enhancing innate humoral
and cellular defense mechanisms (Safarpour et al., 2011). Some
studies have shown that SBOSs may influence hematological
and immunological parameters; for example, SBOSs have been
shown to increase superoxide dismutase levels in the blood,
raise IgG levels, alter the weights and indices of immunity
organs (e.g., bursa of thymus, fabricius, and spleen), promote
splenocyte proliferation, enhance the number of antibody
forming cells (AFCs) in normal mice, and ameliorate harmful
immune effects in SAM- and S180-treated mice (Xu et al.,
2005). These studies have shown that SBOSs have dramatic
effects on gut health and immune modulation. However, the
details of mechanisms through which intestinal microbes and
immune modulation are affected by SBOSs are not known.
While the positive effects of some prebiotics, including FOS,
arabinoxylan-oligosaccharides (AXOSs), and mannan
oligosaccharides (MOSs), have been reported (e.g., growth
performance, innate immunity, hematological and serum bio-
chemical parameters, microbial fermentation, and autochtho-
nous intestinal microbiota (Akrami et al., 2013; Geraylou
et al., 2012; Huynh et al., 2009), the effects of SBOSs onintestinal microbial communities and immune modulation
have not yet been studied in a mouse model.
In this study, we assessed prebiotic effects of SBOSs on the
intestinal microbial communities, including bifidobacteria, lac-
tic acid bacteria (LAB), Escherichia coli, enterococci, and C.
perfringens, in order to evaluate immune responses of mice
consuming different levels of oligosaccharides.
2. Material and methods
2.1. Reagents and animals
SBOSs were purchased from Baolingbao Biological Co.
(Shandong, China). Chicken red blood cells (CRBCs) and lac-
tate dehydrogenase were obtained from Applygen Technolo-
gies Inc. (Beijing, China). Methyl thiazolyl tetrazolium
(MTT) and sodium dodecyl sulfate (SDS) were purchased
from AMRESCO LLC. (Solon, USA). Concanavalin A
(ConA) and erythrocyte lysates were purchased from Sigma-
Aldrich Chemical Co. (St. Louis, MO, USA). Mouse tumor
necrosis factor-a (TNF-a), mouse interleukin-4 (IL-4), and
mouse interferon-c (IFN-c) were purchased from R&D
Systems, Inc. (San Diego, CA, USA). Mouse TNF-a, IL-4,
and IFN-c ELISA kits were purchased from Bogu Biological
Technology Co. (Shanghai, China). Biological stains, includ-
ing Giemsa dye, vice magenta, and malachite green were
obtained from Aojia Chemical Co. (Nanjing, China).
Kunming mice (weighing 22.2 ± 0.6 g each) were obtained
from Biotechnology Co., Ltd. (Liaoning, China) and main-
tained in specific pathogen-free conditions. They had free
access to water and standard rodent chow and were weighed
daily.
2.1.1. Experimental animal grouping
Mice were randomly assigned to four groups: 0 (control
group), 0.5 (low-dose group), 1.5 (middle-dose group), and
4.0 (high-dose group) g kg body weight (BW)1 (n= 20 mice
per group, 10 males and 10 females). Before the experiment,
mouse feces were placed in sterile containers, and the numbers
of fecal bacteria (CFU/g) were determined by using logarithm
statistics. Mice were then treated by intragastric administra-
tion of SBOSs, and the number of fecal bacteria was deter-
mined again at 24 h after the final treatment in weeks 1 and
2. At 24 h after treatment in week 3, 10 mice within each group
(five males and five females) were randomly chosen for analysis
of cellular immunity, natural killer (NK) cell numbers, and
cytokine and immunoglobulin levels. The remaining 10 mice
in each group were used for detection of humoral immunity
and phagocytic activity following transfer of chicken erythro-
cytes into the mice. Feces production, body weights, and water
and food intake were recorded daily throughout the
experiment.
2.2. Analysis of intestinal microbial communities
Under sterile conditions, the intestinal microbial communities
within mouse feces were counted after continuous intragastric
administration of SBOSs for 8.15 or 22 days. Changes in bifi-
dobacteria, lactobacilli, E. coli, enterococci, and C. perfringens
were compared. The effects of SBOSs on the balance of intesti-
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with the Technical Standards for Testing and Assessment
Health Food (2003 Edition, China). Media, culture conditions,
and identification methods are shown in Table 1.
2.3. Analysis of immune modulation parameters
The effects of SBOSs on immune modulation were determined
in accordance with the Technical Standards for Testing and
Assessment Health Food (2003 Edition, China). Cellular
immune function, humoral immune function, macrophagic
phagocytosis, NK cell activity, and cytokine and immunoglob-
ulin levels were determined.
Cellular immunity was evaluated by determining the per-
centages of T-lymphocytes and lymphocytic transformation
induced by ConA in mice using enzyme-labeled staining of
lymphocytes in the peripheral blood. Additionally, MTT
assays were performed to measure changes in cell proliferation
using the differences in optical densities (DOD570).
Humoral immunity was assessed by the analysis of hemoly-
sin using CRBCs as an immune source, and the absorbance
was read spectrophotometrically (Hitachi) at 540 nm.
Phagocytic activity was assessed by incubating phagocytic
cells from the head kidney with CRBCs overnight at 15 C.
Phagocytic activity was determined as the percentage and
index of phagocytic cells quantified from 100 cells observed
under a microscope. The phagocytic percentage and phago-
cytic index were calculated as follows:
Phagocytic percentage
¼ Number of macrophage phagocytozing CRBCs
Number of macrophagesðout of 100 cellsÞ  100
Phagocytic index
¼ Number of phagocytosed CRBCs
Number of macrophagesðout of 100 cellsÞ  100
The activity of NK cells was measured according to previ-
ously described methods using lactate dehydrogenase (LDH)
activity (2003 Edition, China).
Cytokine levels were measured as previously described
(2003 Edition, China), with slight modifications. At 24 h after
the last administration, blood was sampled via retro-orbital
collection. Serum was obtained after centrifugation at
2000 rpm for 10 min and was stored at 20 C. TNF-a,
INF-c, and IL-4 levels in serum were determined by enzyme-
linked immunosorbent assay. Standard wells and test sample
wells were included in the microtiter plate. A set of serial dilu-Table 1 Media, culture conditions, and identification methods of i
Species name Medium Culture co
Bifidobacteria TYG (tryptone yeast glucose extract agar) 37 C, 48 h
anaerobic
LAB EMB (eosin methylene blue medium) 37 C, 24 h
E. coli MRS (Lactobacillus bacteria-selective
medium)
37 C, 48 h
anaerobic
Enterococci SSM (Streptococcus-selective medium) 37 C, 24 h
C. perfringens TSC (tryptone-sulfite cycloserine medium) 37 C, 48 h
anaerobictions of the standard, in a volume of 50 lL, were added into
the standard wells. Ten microliters of each test sample was
added to the appropriate wells, along with 40 lL of sample
diluent. The blank wells were empty. The wells were then
blocked with 100 lL of HRP-conjugated reagent at 37 C for
1 h. After blocking, the plate was washed five times with
400 lL Wash Solution. Fifty microliters of chromogen solu-
tions A and B was added, and the plates were incubated for
15 min at 37 C. The reaction was stopped with 50 lL of Stop
Solution, and the absorbance was measured at 450 nm.
Total immunoglobulin (Ig) was measured by the method
described by Siwicki and Anderson (1993). Serum was sepa-
rated from collected blood as described above, and IgA,
IgG, and IgM contents were determined.
2.4. Statistical analysis
All data were compared using analysis of variance (ANOVA),
and differences between means were evaluated by Duncan’s
Multiple Range Test. The SPSS statistic program (Version
19.0) was used for data analysis.
3. Results
3.1. Effects of different doses of SBOSs on the intestinal
microbial communities in mice
As shown in Fig. 1, the numbers of bifidobacteria, LABs,
E. coli, enterococci, and C. perfringens in control mice did
not change throughout the experiment (p> 0.05). Addition-
ally, there were no significant differences between the low-
dose and control groups for these five types of bacteria follow-
ing treatment for 22 days. However, the middle- and high-dose
groups exhibited significant increases in the number of intesti-
nal bifidobacteria (increased by 13.42% and 16.08%, respec-
tively; p< 0.01). Additionally, after administration of
SBOSs for 8.15 or 22 days, the numbers of LAB in the high-
dose group were significantly increased (by 9.31% and
11.76%, respectively; p< 0.01) when compared to the control
group. Moreover, the number of E. coli was significantly
increased by 7.43% in the high-dose group compared to that
of the control (p< 0.05). Similarly, the numbers of entero-
cocci in the high- and middle-dose groups were significantly
increased (by 6.86% and 8.23%, respectively; p< 0.05) com-
pared to the control.
In contrast, intestinal C. perfringens numbers were signifi-
cantly reduced (by 18.65%; p< 0.01) following administra-ntestinal microbes.
nditions Identification method
, Gram-positive staining of all non-bacillus
Gram-negative staining of all bacilli
, GB/T.4789.34-2003
Gram-positive staining of all cocci and obvious brown
circle
, All fluorescent black colonies under UV
Figure 1 Effects of different doses of SBOSs on intestinal microbes. (Bifidobacteria (A), LAB (B), E. coli (C), enterococci (D), and C.
perfringens (E) (mean ± SD, n= 20) were analyzed. Statistical significance is indicated versus the control group. *p< 0.05, **p< 0.01.
C: colonies.).
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were observed between the control group and the low- or
middle-dose groups (p> 0.05). These findings indicated that
SBOSs had differential effects on the populations of intestinal
microbes and that certain oligosaccharides may inhibit the
growth of specific types of intestinal bacteria.3.2. Effects of SBOSs on nonspecific immunity in mice
The effects of SBOSs on nonspecific immunity in mice are
shown in Fig. 2.First, we measured phagocytosis, an immune process medi-
ated by macrophages (Hume, 2006). Compared with the con-
trol group, high-dose SBOSs enhanced the percentage of
macrophage phagocytosis (p< 0.01) and the phagocytic index
(p< 0.01). However, low-dose SBOSs did not alter these
parameters (p> 0.05). These data indicated that high-dose
SBOSs promoted the phagocytic activity of peritoneal macro-
phages, improving nonspecific immunity.
Next, we analyzed the activity of NK cells, important indi-
cators of the nonspecific immune response, to investigate the
influence of SBOSs on immune function. As shown in Table 2,
the activity of NK cells was dramatically increased in the high-
Figure 2 The activation of SBOS on systemic immunity.
Table 2 Effects of SBOSs on nonspecific immunity in mice.
Groupc Dose
(g kg1)
Phagocytosis of macrophages NK cells Cytokine secretion
Phagocytic percentage
(%)
Phagocytic
index
Activity of NK
cells
INF-c TNF-a IL-4
(ng/mL) (ng/mL) (pg/mL)
Control group 0 22.27 ± 2.45 0.24 ± 0.04 20.21 ± 2.13 94.04 ± 7.29 50.16
± 3.25
16.63
± 1.78
Low-dose group 0.5 23.67 ± 3.10 0.27 ± 0.08 21.15 ± 2.57 101.19
± 4.46
52.22
± 3.65
17.88
± 2.67
Middle-dose
group
1.5 25.96 ± 1.54a 0.36 ± 0.05a 22.36 ± 2.98 109.88
± 5.97a
55.73
± 3.28a
19.24
± 1.56a
High-dose group 4 29.38 ± 2.78b 0.47 ± 0.13b 25.42 ± 2.43a 123.46
± 6.65b
60.87
± 2.83b
23.2
± 2.42b
a p< 0.05.
b p< 0.01 compared to the control group.
c Values shown are mean ± SD (n= 10).
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(p < 0.05).
Cytokines play essential roles in many immune-related pro-
cesses. Therefore, we next analyzed changes in the expression
levels of TNF-a, IFN-c, and IL-4. As shown in Table 2, levels
of TNF-a, INF-c, and IL-4 were significantly increased in the
high-dose group as compared to those in the control group(p< 0.01). In contrast, low-dose SBOSs did not affect the
levels of these cytokines (p> 0.05).
Taken together, these data demonstrated that SBOSs
promoted the activity of monocytes, macrophages, T cells,
B cells, and NK cells and increased cytokine secretion,
supporting the role of SBOSs in modulating immune
function.
Table 3 Effects of SBOSs on specific immunity in mice.
Groupc Dose (g kg1) Cellular immunity Humoral immunity
Percentage of T-lymphocytes Lymphocytic transformation
Percentage (%) Lymphocyte proliferation Hemolysin production(OD540)
(DOD570 D-value)
Control group 0 44.38 ± 2.86 0.161 ± 0.03 0.218 ± 0.028
Low-dose group 0.5 46.72 ± 3.25 0.173 ± 0.05 0.277 ± 0.037a
Middle-dose group 1.5 48.68 ± 2.95a 0.187 ± 0.06 0.322 ± 0.058b
High-dose group 4 54.36 ± 3.12b 0.276 ± 0.07b 0.419 ± 0.069b
a p< 0.05.
b p< 0.01 compared to the control group.
c Values shown are mean ± SD (n= 10).
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The effects of SBOSs on specific immunity (i.e., cellular immu-
nity and humoral immunity) in mice are shown in Table 3.
Cellular immunity was measured by determining the numbers
of T lymphocytes in the peripheral blood using an acid-a-
naphthyl acetate esterase (ANAE) activity assay; this assay
specifically targets T lymphocytes because B lymphocytes lack
the ANEA protein, and hydrolysis of hydrolyze a-naphthyl
acetate, which leads to production of an insoluble red brown
precipitation, is only observed in T lymphocytes. Importantly,
high-dose SBOSs significantly increased the percentage of T
lymphocytes compared to that in control mice (p< 0.01),
indicating that administration of SBOSs promoted cellular
immunity in mice. Additionally, high-dose SBOSs improved
ConA-induced lymphocytic transformation (p< 0.01), while
low- and middle-dose SBOSs did not (p> 0.05). Because lym-
phocyte proliferation is an important indicator of lymphocyte
activation and function, which govern many processes in cellu-
lar immunity (Cerqueira et al., 2004), these data indicated that
high-dose SBOSs stimulated cellular immunity through pro-
moting lymphocyte proliferation.
Hemoglobin content can reflect the level of serum hemoly-
sin, which in turn reflects the state of immune function (Wang
et al., 2002). Therefore, we analyzed the effects of SBOSs on
hemolysin production (Table 3). Hemolysin levels were signif-
icantly higher in all SBOS-treatment groups than in the control
group (p < 0.01 for high- and middle-dose groups and
p< 0.05 for the low-dose group). These data demonstrated
that SBOSs promoted humoral immune function.Table 4 Effects of SBOSs on immunoglobulin content in mouse se
Groupc Dose (g kg1) IgA (
Control group 0 4.46 ±
Low-dose group 500 6.23 ±
Middle-dose group 1500 8.64 ±
High-dose group 4000 11.46
a p< 0.05.
b p< 0.01 compared to the control group.
c Values shown are mean ± SD (n= 10).3.4. Effects of SBOSs on immunoglobulin levels in mice
Immunoglobulins are essential components of the humoral
immune system and have been shown to prevent bacterial
adhesion to the surface of epithelial cells, thereby providing
protection against infection. As shown in Table 4, compared
with the control group, serum levels of IgA, IgG, and IgM
were significantly increased in the high-dose group
(p< 0.01). Additionally, serum IgA and IgG levels were also
significantly increased in the middle-dose group (p< 0.01
and p< 0.05, respectively). Thus, these data demonstrated
that SBOSs enhanced immunoglobulin secretion from the
intestinal mucosa, thereby improving immune function.
4. Discussion
In this study, we investigated the prebiotic functions of SBOSs
in a mouse model. Our data showed that high-dose SBOSs
(4.0 g kg BW1) induced dramatic changes in all examined
immune parameters, functioning to modulate cellular,
humoral, and nonspecific immune pathways. Therefore, our
data provide important insights into the role of SBOSs as
prebiotics.
Intestinal epithelial cells are in direct contact with the
microbiota in the gut lumen. Kagnoff and Eckmann (1997)
are thought to participate in the onset and regulation of the
mucosal immune response to bacteria, especially pathogens,
by interacting with the immune cells of Peyer’s patches, lym-
phoid tissue in the lamina propria of the gut, and intraepithe-
lial lymphocytes. Prebiotics can enhance innate immunerum.
g/L) IgG (g/L) IgM (g/L)
1.29 1.33 ± 0.52 0.57 ± 0.17
2.32 2.03 ± 0.95 0.59 ± 0.15
1.77b 2.32 ± 0.78a 0.71 ± 0.26
± 2.73b 2.77 ± 0.83b 1.31 ± 0.33b
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cytotoxic activity of NK cells (Arnold et al., 2006). The activa-
tion of neutrophils and NK cells may be closely connected with
the anti-infectious or anticancer activities of prebiotics. More-
over, the use of prebiotics may reinforce innate function.
Indeed, studies have shown that dietary supplementation with
Lactobacillus rhamnosus HN001 increases NK cell numbers in
humans (Gill et al., 2001) and consumption of L. casei Shirota
fermented milk enhances the cytotoxic activity of NK cells
(Takeda et al., 2006).
In our study, high-dose SBOSs modulated the numbers of
bifidobacteria and LABs and caused changes in immunological
parameters in mice. Under established conditions of intestinal
microbial community colonization, SBOSs enhanced the acti-
vation, proliferation, and differentiation of T cells into effec-
tive T cells that secreted increased levels of IFN-c, TNF-a,
and IL-4. Moreover, our data demonstrated that intestinal
immunity was activated, as measured by analyzing
T-lymphocyte percentages, lymphocytic transformation, and
cytokine secretion. The increase in IgA, IgG, and IgM and evi-
dence of enhanced humoral immunity indicated the occurrence
of lymphoid follicular hyperplasia and increased B-cell pro-
duction, both of which can lead to increases in immunoglobu-
lin secretion. The enhanced phagocytic activity of
macrophages and killing ability of NK cells promote the abil-
ity of T cells to identify targets and stimulate the immune
response indirectly (Feng et al., 2010). In adaptive immunity,
many prebiotic bacteria can stimulate IgA secretion by B cells
and the activation of helper T lymphocytes and macrophages
by increasing production of cytokines, which are involved in
communication between lymphocytes, macrophages, and other
cells involved in inflammatory reactions and immune
responses (Arseneau et al., 2007). In addition, there is a wide
variation in the response of cytokines induced by different
strains or species of prebiotics (Flickinger and Fahey, 2002).
Therefore, measurement of these varied representative immune
system markers provided a broad view of the effects of SBOSs
on immunity function.
The intestinal mucosal immune system is an important part
of the local immune system and is considered the first barrier
of the immune system (Guoping et al., 2000), playing an
important role in resisting the invasion of bacteria, viruses,
and toxins (Kwon et al., 2002; Blaschitz and Raffatellu,
2010). Many immunoreactive substances first contact the body
via the gut after oral administration or consumption, thus
resulting in systemic immune system induction
(Challacombe, 1983). Intestinal lymphocytes are produced by
the intestinal lymph tissue itself, especially the PP knot, which
is the main location of induction of intestinal mucosal immu-
nity; indeed, antigen uptake, immune response, and regulation
of IgA generation and other effects occur in the intestinal
lymph tissue. In vitro application of SBOSs had no significant
effect on the proliferation of spleen cells and Peyer’s Patchs
(Xu et al., 2005), indicating that the stimulatory effect of
SBOSs on immune function was not due to its direct activation
of immune cells. In the intestine, SBOSs can promote the pro-
liferation of bifidobacteria and lactobacilli, which can be used
as nonspecific regulatory factors to affect intestinal mucosal
immune dysfunction (Huang et al., 2006) In addition, bifi-
dobacteria and lactobacilli can produce large amounts of lactic
acid and acetic acid, which can inhibit the growth of E. coli
and enterococci, thereby increasing the probability of intesti-nal mucosal colonization and limiting the contact of the
intestinal epithelium with pathogenic bacteria and their toxins.
In conclusion, our current study provided further support
for the prebiotic functions of high-dose SBOSs; in mice, this
dose positively affected the intestinal microbial communities
and enhanced immunological parameters. With increasing
concerns about prebiotic use in the food industry, we suggest
that a combination of pro- and prebiotics as symbiotics may
be needed to obtain beneficial effects in practice.
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